{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-023529","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.969066+00:00","generated_at":"2026-06-19T06:47:41.145405+00:00","sec_items":["1.01","1.02","2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Esperion Q4 2022 revenue $18.8M (+22% YoY); CLEAR Outcomes trial meets MACE-4 endpoint","bullets":["CLEAR Outcomes trial met primary MACE-4 endpoint and key secondary endpoints; data to be presented at ACC.23/WCC on March 4, 2023.","Q4 2022 U.S. net product revenue $15.0M (+23% YoY); full year $55.9M (+40% YoY).","Net loss Q4 $55.5M ($0.76 per share) vs $65.1M ($1.77) in Q4 2021; full year net loss $233.7M ($3.52) vs $269.1M ($9.31).","SG&A expenses decreased 37% in Q4 and 41% for full year 2022 vs 2021.","Entered new $70M ATM sales agreement with Cantor Fitzgerald; terminated prior $250M ATM with Jefferies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-023529","json":"https://secwatch.observer/filing/0001104659-23-023529.json","markdown":"https://secwatch.observer/filing/0001104659-23-023529.md","text":"https://secwatch.observer/filing/0001104659-23-023529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/0001104659-23-023529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/tm237313d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:47:41.145405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb4648297cda50461720c3c4984e06e5ac493ad2","claim":"Esperion Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $18.8 million, net income net losses of $55.5 million for the fourth quarter of 2022 and $233.7 million for the full year ended December 31, 2022, EPS basic and diluted net losses per share of $0.76 for the fourth quarter of 2022 and $3.52 for the year ended December 31,.","evidence_excerpt":"consumer and brand awareness in their national fanbase Fourth Quarter and Full Year 2022 Financial Results Total revenue for the fourth quarter ended December 31, 2022, was $18.8 million and $75.5 million for the full year ended December 31, 2022, compared to $15.4 million and $78.4 million for the comparable periods in 2021, an increase of 22% and a decrease of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/0001104659-23-023529-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$18.8 million"},{"label":"Net income","value":"net losses of $55.5 million for the fourth quarter of 2022 and $233.7 million for the full year ended December 31, 2022"},{"label":"EPS","value":"basic and diluted net losses per share of $0.76 for the fourth quarter of 2022 and $3.52 for the year ended December 31,"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c9ff915244a4d6470983afb18f11a2aecfe36222","claim":"Esperion Therapeutics, Inc. terminated Open Market Sale Agreement with Jefferies LLC valued at the Company terminated the 2021 Sales Agreement, effective as of February 21, 2023 (effective 2023-02-21).","evidence_excerpt":"In connection with the Company’s entry into the 2023 Sales Agreement, the Company terminated the 2021 Sales Agreement, effective as of February 21, 2023, pursuant to Section 7(b)(i) thereof.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/0001104659-23-023529-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"the Company terminated the 2021 Sales Agreement, effective as of February 21, 2023"},{"label":"Effective","value":"2023-02-21"}],"fact_type":"material_agreement"},{"claim_id":"f102c78f877b3d491bf91dc3573e05079b70b99c","claim":"Esperion Therapeutics, Inc. entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. valued at up to $70,000,000 of shares of the Company's common stock (effective 2023-02-21).","evidence_excerpt":"On February 21, 2023, Esperion Therapeutics, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “2023 Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, up to an aggregate of $70,000,000 of shares of the Company’s common stock, $0.001 par value per share (the “Shares”), through the Agent, as the Company’s sales agent (the “ATM Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/0001104659-23-023529-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"up to $70,000,000 of shares of the Company's common stock"},{"label":"Effective","value":"2023-02-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}